Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 31;11(4):e006434.
doi: 10.1136/rmdopen-2025-006434.

Concordance between presenting features and relapse in granulomatosis with polyangiitis: implications for risk assessment and counselling

Collaborators, Affiliations

Concordance between presenting features and relapse in granulomatosis with polyangiitis: implications for risk assessment and counselling

Michele Iudici et al. RMD Open. .

Abstract

Objective: To investigate the concordance between organ involvement at diagnosis and relapse in granulomatosis with polyangiitis and factors associated with new disease features at relapse.

Methods: Data from a national database of newly diagnosed patients was analysed. Clinical features were recorded at diagnosis and relapse, grouped by organ system. ORs and HRs were used to assess associations between baseline features and first relapse. Factors independently associated with new organ involvement at relapse were identified using multivariable logistic regression.

Results: Among 795 patients (median follow-up 3.5 years), 394 (50%) relapsed; organ involvement at relapse was available for 376 patients. Relapses most often affected ear, nose and throat (ENT), lungs and kidneys. Organ involvement at diagnosis was associated with a higher likelihood of relapse in the same organ: eyes (OR 6.69), lungs (OR 3.35), kidneys (OR 3.58), nervous system (OR 2.90), and mucocutaneous (OR 4.53). Major manifestations associated with a higher likelihood of recurrence were scleritis, pachymeningitis, subglottic stenosis and worsening renal function. For 56% of patients, the first relapse affected only the initially involved organs. Of the 165 patients with new organ manifestations, these were rarely isolated (n=34) and usually occurred alongside involvement of at least one previously affected organ (n=131). In multivariable analysis, systemic, ENT and lung manifestations at diagnosis were associated with a lower risk of new organ disease at relapse.

Conclusion: Although new features can still emerge, organ involvement at diagnosis is associated with a higher likelihood of relapse in the same organ.

Keywords: Epidemiology; Granulomatosis with polyangiitis; Vasculitis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Professor Puéchal has received consulting fees, speaking fees, honouraria and/or funding for congress registration/travel/accommodation from Boehringer Ingelheim, Sanofi, AstraZeneca, GlaxoSmithKline (less than $10 000 each). Professor Iudici has received consulting fees and speaking fees from Boehringer Ingelheim and Vifor Pharma. Professor Terrier has received consulting fees, speaking fees and honouraria from Lilly, GlaxoSmithKline, Bristol Myers Squibb, AstraZeneca, LFB, Grifols and Vifor (less than $10 000 each). All the authors have been coinvestigators in academic studies for which rituximab was provided by Roche Pharma. No other conflicts of interest are reported. Drs Cohen and Guillevin have no conflicts of interest.

Figures

Figure 1
Figure 1. Sankey diagrams showing flows from organ manifestations present at diagnosis (left) to organ manifestations present at first relapse (right) (left panel); flows from organ involvement absent at diagnosis (left) to the organ involved at first relapse (right) (right panel). Link width is proportional to the number of patients. Flows with small counts are omitted for readability (threshold ≥10 patients). Each patient may contribute multiple links when multiple organs are involved. ENT, ear, nose and throat; GI, gastrointestinal.
Figure 2
Figure 2. Sankey diagram illustrating relapse occurrence among all patients and its subdivision according to whether new organ involvement was present at first relapse.

References

    1. Kronbichler A, Bajema IM, Bruchfeld A, et al. Diagnosis and management of ANCA-associated vasculitis. Lancet. 2024;403:683–98. doi: 10.1016/S0140-6736(23)01736-1. - DOI - PubMed
    1. Iudici M, Pagnoux C, Courvoisier DS, et al. Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. Semin Arthritis Rheum. 2021;51:339–46. doi: 10.1016/j.semarthrit.2021.02.002. - DOI - PubMed
    1. Floege J, Jayne DRW, Sanders J-SF, et al. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis. Kidney Int. 2024;105:S71–116. doi: 10.1016/j.kint.2023.10.008. - DOI - PubMed
    1. Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83:30–47. doi: 10.1136/ard-2022-223764. - DOI - PubMed
    1. Terrier B, Darbon R, Durel C-A, et al. French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides) Orphanet J Rare Dis. 2020;15:351. doi: 10.1186/s13023-020-01621-3. - DOI - PMC - PubMed